Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
cancer
7
×
detroit blog main
detroit top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
7
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national
deals
europe blog main
europe top stories
fda
alzheimer's disease
eli lilly
ipo
novartis
takeda pharmaceutical
abbvie
biogen
What
bio
roundup
life
sciences
acquisitions
buy
ceo
companies
covid
daniel
debut
gilead
ipo
medicines
moves
new
o’day
science
week
years
activity
admits
ago
alliance
announced
approvals
bails
big
biggest
biogen
biotechs
black
brand
bridgebio
bristol
build
calls
capital
car
changing
Language
unset
7
×
Current search:
cancer
×
startups
×
" raleigh-durham top stories "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In